Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.39 |
| ▸ | ACACB | O00763 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29270939 | 1.00 | FFAR4 (0.39) | FFAR4ACACBKMT2AALDH1A1TSHR | |
| SCHEMBL29270941 | 1.00 | FFAR4 (0.39) | FFAR4ACACBKMT2AALDH1A1TSHR | |
| SCHEMBL23039953 | 0.86 | FFAR4 (0.38) | FFAR4ACACBKMT2AALDH1A1TSHR | |
| SCHEMBL23040236 | 0.86 | FFAR4 (0.38) | FFAR4ACACBKMT2AALDH1A1TSHR | |
| SCHEMBL23055156 | 0.81 | DGKZ (0.43) | ACACBKMT2A | |
| SCHEMBL27878721 | 0.78 | FFAR4 (0.44) | FFAR4KMT2AFFAR1 | |
| SCHEMBL23182928 | 0.77 | ALDH1A1 (0.44) | FFAR4KMT2AALDH1A1 | |
| SCHEMBL24658820 | 0.77 | RXRA (0.39) | FFAR4ALDH1A1TSHRFFAR1 | |
| SCHEMBL23039979 | 0.74 | ALDH1A1 (0.47) | FFAR4KMT2AALDH1A1 | |
| SCHEMBL28750680 | 0.74 | ALDH1A1 (0.47) | FFAR4KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-4021901-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | FFAR4 2492/4885ACACB 3811/4885KMT2A 2162/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | FFAR4 2492/4885ACACB 3811/4885KMT2A 2162/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | FFAR4 2638/4885ACACB 3307/4885KMT2A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.